Research by Breakthrough Breast Cancer scientists has revealed a new sensitive method that may help identify additional women who could benefit from the drug trastuzumab (Herceptin). Results published in the Journal of Pathology on Friday 6 August suggest that the way in which HER2 positive breast cancers are currently identified may miss a small number of patients that could benefit from targeted therapies against HER2.
More...